Observational studyJournal of gastrointestinal cancer2026
Model-Based Prognostication and Symptom Distress in Patients with Advanced Hepatopancreaticobiliary Cancers Receiving Best Supportive Care: A Prospective Cohort Study.
Observational study in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetastatic hepatopancreaticobiliary (HPB) cancers often exhibit rapid and aggressive progression. Accurate prognostication is essential for aligning care objectives and preventing futile interventions. The Palliative Prognostic Index (PPI) is a simple, validated bedside tool for advanced cancers, but its efficacy in metastatic HPB malignancies remains unassessed. This study aimed to evaluate the predictive accuracy of the PPI and to describe the symptom burden in this patient population.
methodsWe conducted a prospective observational cohort study of adults with metastatic HPB cancers referred for specialist palliative care from September 2022 to May 2023 who were not receiving any disease directed treatment. Baseline PPI scores were determined by palliative care physicians and survival was documented for 90 days. Symptom burden was assessed using the Edmonton Symptom Assessment Scale (ESAS). The prognostic performance of the PPI was evaluated using c-statistic and sensitivity-specificity analyses.
resultsAmong 145 participants, 123 (84.8%) died within 90 days. Median actual survival was 24 days (95% CI: 20.8–27.2). PPI showed good discrimination (c = 0.78 at 7 days, 0.71 at 21 days). Higher PPI categories were significantly associated with greater mortality risk (HR 2.61, 95% CI: 1.56–4.36). Performance status and presence of abdominal pain independently predicted mortality. Significant baseline symptom distress was seen, with modest alleviation after palliative care integration.
conclusionIn metastatic HPB cancers, PPI offers a practical and specific adjunct to clinical judgment for short-term survival estimation in palliative settings. Further validation in disease specific cohorts is needed to improve prognostic precision and guide care planning in patients with advanced cancer. TRN: CTRI/2022/08/044932 Date of registration:25/08/2022.
Indexed as
Identifiers
41999526What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.